Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy ...

JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...

Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

“We have a longstanding and productive partnership with Amneal, and we are pleased to be advancing these two important products to the U.S. biosimilar market. We remain focused on our globalization ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

In addition, we will continue to build on our industry-leading pipeline across generics and biosimilars. Our 2025 guidance and mid-term outlook reflect the confidence we have in the strategic ...